Fosaprepitant

فوس‌آپری‌پیتانت

⚠ Unverified

🍽️ Alimentary Tract And MetabolismNK1 receptor antagonist (IV)

Market / country: 🇺🇸 USA

Emend IV (US)

🧮 Dose calculator

Chemotherapy-induced nausea and vomiting · Regimen source: FDA Fosaprepitant · 2.1

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

Warnings

  • • Clinically significant CYP3A4 interactions; decreased INR with warfarin (monitor days 7–10); reduced hormonal contraceptive efficacy for 28 days. FDA Fosaprepitant · 5
  • • Hypersensitivity reactions; infusion-site reactions. FDA Fosaprepitant · 5

Formulations

👥 Special populations

  • 🤰 PregnancyUse with caution

    Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Fosaprepitant · 8.1

    “Risk Summary There are insufficient data on use of fosaprepitant in pregnant women to inform a drug associated risk.”
  • 🤱 BreastfeedingUse with caution

    Label: use with caution while breastfeeding; see the label text. FDA Fosaprepitant · 8.2

    “Risk Summary Lactation studies have not been conducted to assess the presence of aprepitant in human milk, the effects on the breastfed infant, or the effects on milk production.”
  • 👶 ChildrenUse with caution

    The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Fosaprepitant · 8.4

    “The safety and effectiveness of a single dose and a 3-day regimen of fosaprepitant have been established in pediatric patients 6 months to 17 years for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC and MEC.”
  • 👴 Older adultsUse with caution

    Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Fosaprepitant · 8.5

    “In general, use caution when dosing elderly patients as they have a greater frequency of decreased hepatic, renal or cardiac function and concomitant disease or other drug therapy [see Clinical Pharmacology (12.3) ].”
  • ⚥ Females & males of reproductive potentialUse with caution

    Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Fosaprepitant · 8.3

    “Contraception Upon administration of fosaprepitant, the efficacy of hormonal contraceptives may be reduced.”

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

🔗 Similar drugs

Doz is only a support tool and does not replace clinical judgment or official sources. Check every dose against the original source before prescribing. About & disclaimer · Sources

Information on this site is compiled from online websites and references. Doz accepts no responsibility for self-medication without approval from a physician and a reliable reference, or for any consequences of using this information.

Inspired by the Saphira project; part of the content is taken from it.

For suggestions, corrections, adding drugs or anything else, you can contact me on Telegram: @cenaav